Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This research study is studying the combination of daratumumab with weekly carfilzomib,
pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma.
Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment
resistant Multiple Myeloma.
This research study involves two study drugs and two standard of care drugs.
- The names of the study drugs involved in this study are:
- Carfilzomib
- Daratumumab
- The names of the standard of care drugs involved in this study are:
- Dexamethasone
- Pomalidomide